Seventure Partners predicts bright future for microbiome opportunities

April 26, 2017 Christoph Graener

Seventure Partners’ Eric de la Fortelle explains to Informa Pharma Intelligence’s Mike Ward how the venture capitalist’s EUR 160 billion fund will prosper from the increased understanding of human and microbe interactions. Seventure has just published a report on the emergence of the microbiome as an intense area of interest in the biotech industry, starting with the advent of deep sequencing technology in the early 2000s and moving toward the Phase II trials in progress now.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Eric de la Fortelle – Venture Partner, Seventure Partners

Previous Article
Ergomed’s evolution and risk-sharing business model in practice

Andrew Mackie, chief business officer of Ergomed, talks to Scrip about the company's transformation from a ...

Next Article
Atriva repurposes cancer drug candidates to create universal flu treatment

Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, explains how his company is taking kinase inhibitors ...